Market Summary
USD191.28+2.48
Market Closed1.31%
STE Alerts
STE Stock Price
STE RSI Chart
STE Valuation
STE Price/Sales (Trailing)
STE Profitability
STE Fundamentals
STE Revenue
STE Earnings
Price Action
52 Week Range
158.76254.11
(Low)(High)
Last 7 days
3.3%
Last 30 days
1.5%
Last 90 days
3.6%
Trailing 12 Months
-20.3%
STE Financial Health
STE Investor Care
Peers (Alternatives to STERIS)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 108.0B | 18.4B | 9.81% | 7.15% | 45.81 | 5.86 | 7.84% | 18.25% |
MDT | 107.3B | 30.8B | -1.78% | -26.78% | 26.38 | 3.49 | -3.19% | -17.38% |
ISRG | 89.4B | 6.2B | 12.38% | -15.32% | 67.62 | 14.37 | 8.97% | -22.43% |
BDX | 70.1B | 19.0B | 7.04% | -3.24% | 43.54 | 3.69 | -0.43% | -8.78% |
EW | 50.3B | 5.4B | 3.61% | -29.72% | 33.07 | 9.35 | 2.86% | 1.25% |
| MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 14.55% | 4.57% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.6B | 847.1M | 7.86% | 25.46% | -5.3K | 12.54 | 13.32% | -137.89% |
GMED | 5.6B | 1.0B | -2.14% | -23.23% | 32.76 | 5.52 | 6.76% | 24.45% |
IRTC | 3.7B | 410.9M | 4.99% | -21.24% | -32.24 | 9.11 | 27.29% | -14.60% |
TNDM | 2.6B | 801.2M | 10.62% | -65.08% | -27.7 | 3.27 | 14.00% | -707.69% |
| SMALL-CAP | ||||||||
SILK | 1.5B | 138.6M | -18.17% | -5.23% | -27.28 | 10.83 | 36.62% | -10.44% |
AVNS | 1.4B | 820.0M | 5.46% | -11.22% | 27.4 | 1.69 | 10.13% | 701.59% |
BLFS | 928.9M | 154.8M | -4.61% | -4.31% | -8.93 | 6 | 60.29% | -2309.58% |
CSII | 833.4M | 239.8M | 0.46% | -12.12% | -22.01 | 3.47 | -4.74% | -31.15% |
Financials for STERIS
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 0.1% | 4,784 | 4,777 | 4,773 | 4,585 | 4,248 |
| Gross Profit | -0.8% | 2,143 | 2,160 | 2,108 | 2,016 | 1,825 |
| Operating Expenses | -0.2% | 2,009 | 2,013 | 1,538 | 1,591 | 1,347 |
| S&GA Expenses | -0.4% | 1,417 | 1,422 | 1,444 | 1,503 | 1,270 |
| R&D Expenses | 0.7% | 101 | 101 | 95.00 | 88.00 | 79.00 |
| EBITDA | 0.5% | 777 | 773 | 1,177 | 957 | - |
| EBITDA Margin | 0.4% | 0.16* | 0.16* | 0.25* | 0.21* | - |
| Earnings Before Taxes | -39.6% | 34.00 | 56.00 | 478 | 315 | 379 |
| EBT Margin | -39.7% | 0.01* | 0.01* | 0.10* | 0.07* | - |
| Interest Expenses | 6.0% | 99.00 | 94.00 | 90.00 | 90.00 | 78.00 |
| Net Income | -243.2% | -27.93 | -8.14 | 377 | 244 | 279 |
| Net Income Margin | -242.7% | -0.01* | 0.00* | 0.08* | 0.05* | - |
| Free Cahsflow | -12.4% | 349 | 399 | 472 | 397 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 3.0% | 10,800 | 10,490 | 11,188 | 11,424 | 11,690 |
| Current Assets | 4.7% | 1,977 | 1,888 | 1,848 | 1,879 | 1,927 |
| Cash Equivalents | 0.4% | 259 | 258 | 316 | 348 | 359 |
| Inventory | 7.7% | 694 | 645 | 620 | 575 | 595 |
| Net PPE | 6.3% | 1,671 | 1,572 | 1,573 | 1,553 | 1,522 |
| Goodwill | 4.0% | 3,853 | 3,705 | 4,321 | 4,404 | 5,115 |
| Liabilities | 1.6% | 4,751 | 4,676 | 4,769 | 4,879 | 5,066 |
| Current Liabilities | -8.7% | 796 | 873 | 908 | 922 | 904 |
| . Short Term Borrowings | -60.3% | 60.00 | 151 | 151 | 143 | 128 |
| Long Term Debt | - | 2,945 | - | - | - | - |
| LT Debt, Non Current | 4.4% | 3,002 | 2,874 | 2,846 | 2,945 | 3,175 |
| Shareholder's Equity | 3.9% | 6,038 | 5,813 | 6,419 | 6,532 | 6,624 |
| Retained Earnings | 4.5% | 1,771 | 1,695 | 2,057 | 1,999 | 1,990 |
| Shares Outstanding | -0.5% | 99.00 | 100 | 100 | 100 | 100 |
| Minority Interest | -10.4% | 10.00 | 11.00 | 12.00 | 12.00 | 12.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -5.2% | 713 | 752 | 819 | 685 | 701 |
| Share Based Compensation | -1.6% | 40.00 | 40.00 | 40.00 | 58.00 | 54.00 |
| Cashflow From Investing | -9.6% | -212 | -193 | -172 | -666 | -878 |
| Cashflow From Financing | 10.6% | -581 | -650 | -844 | 116 | 294 |
| Dividend Payments | 2.2% | 180 | 176 | 172 | 163 | 154 |
| Buy Backs | 80.4% | 182 | 101 | 70.00 | 56.00 | 28.00 |
Risks for STE
What is the probability of a big loss on STE?
35.4%
Probability that STERIS stock will be more than 20% underwater in next one year
29.2%
Probability that STERIS stock will be more than 30% underwater in next one year.
0%
Probability that STERIS stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does STE drawdown profile look like?
Y-axis is the maximum loss one would have experienced if STERIS was unfortunately bought at previous high price.
Drawdowns
Returns for STE
Cumulative Returns on STE
17.7%
10-Year Cumulative Returns
16.2%
7-Year Cumulative Returns
16.5%
5-Year Cumulative Returns
11.9%
3-Year Cumulative Returns
What are the long-term rolling returns for STE?
FIve years rolling returns for STERIS.
Annualized Returns
Which funds bought or sold STE recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-27 | Neo Ivy Capital Management | reduced | -66.05 | -134,000 | 81,000 | 0.06% |
2023-03-23 | ETF MANAGERS GROUP, LLC | added | 4.16 | 73,944 | 545,944 | 0.03% |
2023-03-17 | American Portfolios Advisors | added | 12.41 | -36,438 | 354,010 | 0.01% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 16.34 | 63,025 | 284,025 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 30.38 | 2,549,500 | 8,238,500 | 0.01% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 20.95 | 5,346,000 | 20,917,000 | 0.10% |
2023-03-03 | TIAA, FSB | reduced | -14.87 | -16,577 | 284,423 | -% |
2023-02-28 | Voya Investment Management LLC | added | 2.61 | 797,247 | 6,511,250 | 0.01% |
2023-02-27 | Gallagher Benefit Services, Inc. | new | - | 216,446 | 216,446 | 0.04% |
2023-02-24 | SRS Capital Advisors, Inc. | reduced | -4.91 | 4,119 | 75,119 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
STE Alerts
STERIS News
Schedule 13G FIlings of STERIS
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 10, 2023 | wcm investment management, llc | 5.6% | 5,563,771 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 11.99% | 11,966,040 | SC 13G/A | |
| Feb 08, 2023 | blackrock inc. | 8.7% | 8,710,879 | SC 13G | |
| Feb 08, 2023 | massachusetts financial services co /ma/ | 5.0% | 5,038,403 | SC 13G | |
| Feb 03, 2022 | blackrock inc. | 8.1% | 8,128,575 | SC 13G/A | |
| Feb 11, 2021 | janus henderson group plc | 3.8% | 3,253,302 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.58% | 9,025,143 | SC 13G/A | |
| Feb 01, 2021 | blackrock inc. | 9.0% | 7,688,347 | SC 13G/A | |
| Feb 13, 2020 | janus henderson group plc | 6.5% | 5,482,611 | SC 13G/A | |
| Feb 06, 2020 | blackrock inc. | 8.7% | 7,337,284 | SC 13G |
STE Fair Value
STERIS fair value in different scenarios
The table shows the Fair Value estimates for STERIS for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 93.54 -51.10% | 124.94 -34.68% | 221.37 15.73% | 295.34 54.40% | 363.68 90.13% |
| Current Inflation | 86.36 -54.85% | 113.22 -40.81% | 195.01 1.95% | 256.43 34.06% | 313.07 63.67% |
| Very High Inflation | 77.57 -59.45% | 99.18 -48.15% | 164.28 -14.12% | 211.75 10.70% | 255.45 33.55% |
Historical STERIS Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of STERIS
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 07, 2023 | 4 | Insider Trading | |
| Feb 17, 2023 | 4 | Insider Trading | |
| Feb 10, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 08, 2023 | SC 13G | Major Ownership Report | |
| Feb 08, 2023 | SC 13G | Major Ownership Report | |
| Feb 08, 2023 | 8-K | Current Report | |
| Feb 08, 2023 | 10-Q | Quarterly Report |
Latest Insider Trading transactions for STE
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-03 | Majors Cary L | sold | -218,742 | 190 | -1,150 | svp and president, healthcare |
2023-02-15 | Breeden Richard C | acquired | 204,535 | 43.92 | 4,657 | - |
2022-12-02 | Xilas Andrew | acquired | - | - | 333 | svp and gm, dental |
2022-12-02 | Xilas Andrew | sold (taxes) | -18,807 | 191 | -98.00 | svp and gm, dental |
2022-12-01 | Majors Cary L | sold | -308,016 | 192 | -1,600 | svp and president, healthcare |
2022-10-10 | Xilas Andrew | sold (taxes) | -25,115 | 168 | -149 | svp and gm, dental |
2022-10-10 | Xilas Andrew | acquired | - | - | 503 | svp and gm, dental |
2022-10-07 | Xilas Andrew | acquired | - | - | 606 | svp and gm, dental |
2022-10-07 | Xilas Andrew | sold (taxes) | -30,464 | 170 | -179 | svp and gm, dental |
2022-10-03 | Zangerle John Adam | sold (taxes) | -15,476 | 170 | -91.00 | sr. vp, gen counsel, and sec. |
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company was founded in 1985 and is based in Dublin, Ireland.
STE Income Statement
2022-09-30CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
| Revenues: | ||||
| Revenues | $ 1,200,517 | $ 1,196,985 | $ 2,357,008 | $ 2,165,407 |
| Fair value adjustment related to convertible debt liability | 0 | 4,883 | 0 | 27,806 |
| Cost of revenues: | ||||
| Total cost of revenues | 668,182 | 716,641 | 1,306,875 | 1,258,781 |
| Gross Profit | 532,335 | 480,344 | 1,050,133 | 906,626 |
| Operating expenses: | ||||
| Selling, general, and administrative | 323,195 | 344,799 | 657,821 | 738,551 |
| 2591744000 | 490,565 | 0 | 490,565 | 0 |
| Research and development | 24,928 | 18,832 | 49,679 | 37,024 |
| Restructuring Costs | 62 | 210 | 88 | 224 |
| Total operating expenses | 838,750 | 363,841 | 1,198,153 | 775,799 |
| Income from operations | (306,415) | 116,503 | (148,020) | 130,827 |
| Non-operating expenses, net: | ||||
| Interest expense | 26,123 | 23,036 | 48,797 | 44,848 |
| Interest income and miscellaneous expense | 524 | (1,023) | 1,294 | (2,457) |
| Total non-operating expenses, net | 26,647 | 26,896 | 50,091 | 70,197 |
| Income before income tax expense | (333,062) | 89,607 | (198,111) | 60,630 |
| Income tax expense | (17,831) | 19,982 | 6,365 | 12,907 |
| Net Income | (315,231) | 69,625 | (204,476) | 47,723 |
| Less: Net Income Attributable to Noncontrolling Interest | 54 | (186) | (453) | (281) |
| Net income (loss) attributable to shareholders | $ (315,285) | $ 69,811 | $ (204,023) | $ 48,004 |
| Net income per common share [Abstract] | ||||
| Basic | $ (3.15) | $ 0.70 | $ (2.04) | $ 0.51 |
| Diluted | (3.15) | 0.69 | (2.04) | 0.50 |
| Cash dividends declared per common share outstanding | $ 0.47 | $ 0.43 | $ 0.90 | $ 0.83 |
| Product [Member] | ||||
| Revenues: | ||||
| Revenues | $ 666,394 | $ 685,238 | $ 1,303,470 | $ 1,174,517 |
| Cost of revenues: | ||||
| Cost of Goods and Services Sold | 351,079 | 427,484 | 683,934 | 698,890 |
| Service [Member] | ||||
| Revenues: | ||||
| Revenues | 534,123 | 511,747 | 1,053,538 | 990,890 |
| Cost of revenues: | ||||
| Cost of Goods and Services Sold | $ 317,103 | $ 289,157 | $ 622,941 | $ 559,891 |
STE Balance Sheet
2022-09-30CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Mar. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 258,259 | $ 348,320 |
| Accounts receivable (net of allowances of $22,196 and $24,371 respectively) | 780,113 | 799,041 |
| Inventories, net | 644,936 | 574,999 |
| Prepaid expenses and other current assets | 204,991 | 156,637 |
| Total current assets | 1,888,299 | 1,878,997 |
| Property, plant, and equipment, net | 1,572,398 | 1,552,576 |
| Operating Lease, Right-of-Use Asset | 174,073 | 188,480 |
| Goodwill | 3,705,140 | 4,404,343 |
| Intangible Assets, Net (Excluding Goodwill) | 3,077,492 | 3,328,537 |
| Other assets | 72,234 | 70,661 |
| Total assets | 10,489,636 | 11,423,594 |
| Current liabilities: | ||
| Accounts payable | 233,308 | 225,737 |
| Accrued income taxes | 16,661 | 26,873 |
| Accrued payroll and other related liabilities | 133,839 | 183,721 |
| Capital Lease Obligations, Current | 33,968 | 36,472 |
| Short-term Debt | 151,000 | 142,875 |
| Accrued expenses and other | 304,039 | 306,544 |
| Total current liabilities | 872,815 | 922,222 |
| Long-term indebtedness | 2,873,936 | 2,945,481 |
| Deferred Income Taxes and Other Tax Liabilities, Noncurrent | 710,087 | 780,619 |
| Capital Lease Obligations, Noncurrent | 143,451 | 155,056 |
| Other Liabilities, Noncurrent | 75,900 | 75,579 |
| Total liabilities | 4,676,189 | 4,878,957 |
| Commitments and contingencies (see Note 8) | ||
| Common shares, with $0.001 par value; 500,000 authorized; 99,868 shares issued; and 100,067 shares outstanding | 4,705,118 | 4,742,920 |
| Retained earnings | 1,695,087 | 1,999,244 |
| Accumulated other comprehensive income | (598,148) | (209,808) |
| Total shareholders' equity | 5,802,057 | 6,532,356 |
| Noncontrolling interest | 11,390 | 12,281 |
| Total equity | 5,813,447 | 6,544,637 |
| Total liabilities and equity | $ 10,489,636 | $ 11,423,594 |